RxDoctor Payments Data

Cory Muscara, MD

Family Medicine · West Babylon, NYNPI 1588661615

Payments from drug & device makers

$681in general payments, 2019–2025

Across 24 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$302
  • Novo Nordisk$135
  • Boehringer Ingelheim$118
  • Abbott$36
  • Philips North America LLC$25
  • Lilly USA, LLC$23
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$82,989
Medicare patients
198
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$33,236
JanuviaSitagliptin Phosphate15$22,224
Atorvastatin Calcium149$1,514
Metoprolol Succinate74$1,240
Losartan Potassium82$965
Amlodipine Besylate112$881
Ezetimibe30$823
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide44$757
Levothyroxine Sodium63$735
Metformin Hcl75$683
ClopidogrelClopidogrel Bisulfate30$628
Rosuvastatin Calcium45$555
Tamsulosin Hcl26$543
Lisinopril32$478
Potassium Chloride27$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$33,23620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in West Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →